Site Search
Professionals 659 results
Capabilities 88 results
Region
Winston’s deep experience representing companies and investors across Latin America and the Caribbean has made the firm a “go-to” resource for the strategic development of our clients’ businesses and the vigorous protection of their interests in the region. With broad command of a diverse range of issues within the region’s key industry sectors, we advise Fortune 500 companies, government and quasi-governmental entities, financial institutions, private equity and other investors, domestic and international oil and gas exploration and production companies, refiners and shippers, and a range of commercial and infrastructure developers.
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Industry
Winston is well regarded for deep and broad experience advising clients in the development, construction, financing and refinancing, acquisition, and operation of major infrastructure assets, including several award-winning deals and public-private-partnership (PPPs or P3s) projects in North America, Latin America, and Europe. Recognized for our ability to “take complex issues and boil them down to pragmatic solutions” (Chambers USA 2023), our team represents a diverse mix of participants and stakeholders in a broad range of investments and non-recourse/limited recourse financings, and we have experience working on many of the most complex projects, within aggressive time frames, while employing inventive solutions. Likewise, our lawyers help to identify and quantify roadblocks and risks at an early stage, so that we can help our clients—which include developers and sponsors, a full range of lenders and investors, project owners and operators, governments and their agencies, and other project counterparties—evaluate and, to the extent possible, mitigate or eliminate risk.
Experience 432 results
Experience
|May 2, 2025
Copley Acquisition Corp. Closes $172.5 Million Initial Public Offering
Experience
|April 11, 2025
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
Experience
|April 10, 2025
Titan Acquisition Corp Announces Closing of $276,000,000 Initial Public Offering
Insights & News 7,738 results
Recognitions
|May 14, 2025
|1 Min Read
Winston & Strawn has been recognized as the second most popular international law firm in the Latin America Corporate Counsel Association’s (LACCA) 2024 survey, “Who Represents Latin America’s Biggest Banks?”
The Reg E Reader
|May 14, 2025
|2 Min Read
Jonathan McKernan No Longer CFPB Director Nominee, Bureau Remains in Limbo
Secretary of the Treasury Scott Bessent announced on May 9 that Jonathan McKernan would be nominated to be Undersecretary of Domestic Finance at the Department of the Treasury, effectively withdrawing McKernan’s previous nomination as CFPB Director.[1]
Article
|May 13, 2025
|8 Min Read
The New DOJ Enforcement Policy for Digital Assets: Why Compliance Programs Still Matter
This article was originally published in New York Law Journal. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only.
Other Results 79 results
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)